DDrare: Database of Drug Development for Rare Diseases

35. 天疱瘡
［臨床試験数：87，薬物数：114（DrugBank：37），標的遺伝子数：17，標的パスウェイ数：158］

Searched query = "Pemphigus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ALXN1830; ARGX-113; Acetaminophen; Acetaminophen/paracetamol; Acetate; Antihistamine (cetirizine or equivalent); Azathioprine; CELLCEPT®; CORTANCYL 20 mg; Carboxymethylcellulose; CellCept 500 mg comprimidos recubiertos; CellCept®500 mg comprimidos; Cellcept® in autoimmune bullous dermatoses; Cellulose; Cetirizine; Cohort 1: 1.0 x 10^8 PolyTregs; Cohort 2: 2.5x10^8 PolyTregs; Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine; Cortancyl; Corticosteroids'therapy; Cotton; Cyclophosphamide; DSG3-CAART; Dapsone; Dermoval; Device: Carboxymethylcellulose with ionic silver (Aquacel Ag); Device: Cellulose acetate with petrolatum; Device: Cotton gauze with petrolatum; Device: Nanocrystalline silver (Acticoat); Dexamethasone; Dexamethasone (50mg 1dd6, 3 consecutive days/month); Dexamethasone 0.5mg/5ml solution; Dexamethasone 0.5mg/5ml solution in Mucolox™; EFGARTIGIMOD ALFA; Efgartigimod; Efgartigimod PH20 SC; Efgartigimod alfa; Enbrel (Etanercept); Etanercept; Filgrastim; GLYCINE; GSK1841157; General Corticotherapy; Glycine; Hematopoietic stem cell transplantation; Human interleukin-2; INCB050465; INCB050465 0.3 mg; INCB050465 0.3mg; INCB050465 1.0 mg; INCB050465 1.0mg; INCB050465 2.5mg; INCB050465 HYDROCHLORIDE; INTERLEUKIN-2; IVIg; Ianalumab; Imatinib; Infliximab; Intratect; Intratect 5%; Intravenous immunoglobulin; KC706; MABTHERA; MABTHERA®; MMF; MTX; MabThera; Mabthera; Mabthéra; Mathéra; Methotrexate; Methylprednisolone; Micofenolato mofetilo; Mycophenolate; Mycophenolate Mofetil; Mycophenolate Mofetil (MMF) 3 g/Day; Mycophenolate Mofetil 2 g/Day; Mycophenolate mofetil; OFATUMUMAB; ONO-4059; Ofatumumab; Other: Autologous Platelet rich plasma; Other: IVIg; PI-0824; PREDNISONE; PRN1008; PRN1008 (Rilzabrutinib); PRN1008 Freebase; PRN1008 Oral Tablet; Paracetamol; Parsaclisib; Petrolatum; Prednisolone; Prednisone; Prednisone/Prednisolone; RITUXIMAB; RO0452294/V02; RO1061443/F02; Rapamycin; Recombinant human interleukin-2 (rhIL-2); Rituximab; Rituximab (MABTHERA® or RITUXAN®).; Rituximab and Cyclophosphamide IV; Silver; Sirolimus; Sirolimus (formerly known as Rapamycin); TPM203; Tirabrutinib; Triamcinolone; Triamcinolone Acetonide; VAY736; WATER FOR INJECTION; Water; [NA]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04400994 (ClinicalTrials.gov)	June 20, 2020	27/4/2020	IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus	The Use of IVIG in Combination With Rituximab VS Rituximab as the First Line Treatment of Pemphigus	Pemphigus	Drug: Rituximab;Other: IVIg	The University of Hong Kong	NULL	Recruiting	18 Years	70 Years	All	20	Phase 2	Hong Kong
2	EUCTR2013-000211-24-DE (EUCTR)	01/10/2013	08/07/2013	immunoglobulin infusion as adjuvant therapy in patients with Pemphigus Vulgaris	A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuvant therapy in patients with Pemphigus Vulgaris - IMAT-PV	patients with Pemphigus vulgaris MedDRA version: 16.0;Level: LLT;Classification code 10052802;Term: Pemphigus vulgaris;System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Ruprecht-Karls-University Heidelberg	NULL	Not Recruiting			Female: yes Male: yes	10	Phase 2	Germany
3	NCT00483119 (ClinicalTrials.gov)	April 2007	5/6/2007	Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus	Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus	Pemphigus Vulgaris	Drug: intravenous immunoglobulin;Drug: cyclophosphamide	New York University School of Medicine	NULL	Terminated	18 Years	85 Years	All	9	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04400994
(ClinicalTrials.gov)

June 20, 2020

27/4/2020

IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus

The Use of IVIG in Combination With Rituximab VS Rituximab as the First Line Treatment of Pemphigus

Pemphigus

Drug: Rituximab;Other: IVIg

The University of Hong Kong

NULL

Recruiting

18 Years

70 Years

All

Phase 2

Hong Kong

EUCTR2013-000211-24-DE
(EUCTR)

01/10/2013

08/07/2013

immunoglobulin infusion as adjuvant therapy in patients with Pemphigus Vulgaris

A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuvant therapy in patients with Pemphigus Vulgaris - IMAT-PV

patients with Pemphigus vulgaris
MedDRA version: 16.0;Level: LLT;Classification code 10052802;Term: Pemphigus vulgaris;System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]

Ruprecht-Karls-University Heidelberg

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Germany

NCT00483119
(ClinicalTrials.gov)

April 2007

5/6/2007

Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus

Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus

Pemphigus Vulgaris

Drug: intravenous immunoglobulin;Drug: cyclophosphamide

New York University School of Medicine

NULL

Terminated

18 Years

85 Years

All

Phase 2

United States